Inc/&esheet=54368949&newsitemid=20251203196184&lan=en- US&anchor=HERE&index=3&md5=675d5818719021c0c361f7e8d5fb061a)**TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.****What Happened?**On October 30, 2025, before the market opened, Blue Owl reported financial results for the third quarter of 2025. Blue Owl reported, among other things, fee-related earnings of only $376.2 million, which missed consensus estimates; fee related earnings margins of 57.1%, whic ...

ARE STOCK ALERT: Alexandria Real Estate Equities, Inc. Investors Reminded to Contact BFA Law Prior to the January 26 Deadline in Securities Fraud Class ActionDecember 03, 2025 3:36 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company's senior executives for sec ...

STRIDE STOCK ALERT: Stride, Inc. (LRN) Investors Reminded to Contact BFA Law Prior to the January 12 Deadline in Securities Fraud Class ActionDecember 03, 2025 3:36 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 3, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company's senior executives for securities fraud after significant stock dro ...

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for securities fraud, following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - Investors are encouraged to contact BFA Law before the December 23, 2025 deadline to be appointed to lead the case [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock [3]. - The case is pending in the U.S. District Court for the Northern District of Illinois, titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al. [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations and Stock Performance - During the relevant period, James Hardie misrepresented the strength of its North American fiber cement segment, claiming sustainable customer demand when, in fact, sales were driven by inventory loading by channel partners [5]. - On August 19, 2025, the company reported a 12% decline in North American fiber cement sales, leading to a stock price drop of over 34%, from $28.43 to $18.64 per share [6].

Core Viewpoint - Kaskela Law LLC is investigating the proposed buyout of Electronic Arts Inc. to assess the fairness of the buyout agreement for shareholders [1][2]. Group 1: Buyout Details - On September 29, 2025, EA announced an agreement to be acquired by a consortium led by the Public Investment Fund of Saudi Arabia at a price of $210.00 per share in cash [2]. - Following the transaction's closure, EA shareholders will be cashed out, and the company's shares will cease to be publicly traded [2]. Group 2: Investigation Focus - The investigation aims to determine if the $210.00 per share offer is adequate compensation for EA shares [3]. - It will also examine whether EA's officers or directors violated their fiduciary duties or securities laws in agreeing to the sale at this price [3]. Group 3: Shareholder Communication - EA shareholders are encouraged to contact Kaskela Law LLC to discuss their legal rights and options regarding the transaction [4].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to lead the case, with claims made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire Medical Systems assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would support the rollout [5]. - Contrary to these assurances, the company allegedly failed to prepare clinicians and payors adequately, leading to significant delays and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand [7]. - Following this announcement, Inspire's stock price fell by $42.04 per share, a decline of more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, particularly related to the company's clinical data and the performance of its investigational drug sonelokimab [1][2][5]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients and differentiation from competitors [4]. - Allegations suggest that the clinical data and the Nanobody structure of sonelokimab did not provide a superior clinical benefit, raising concerns about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Viewpoint - Jefferies Financial Group Inc. and its trade finance arm, Point Bonita Capital, are under investigation for potential violations of federal securities laws following a probe by the SEC related to their exposure to First Brands Group, which filed for bankruptcy in September 2025 [1][4]. Group 1: Company Overview - Jefferies is an investment banking and capital markets firm, with Point Bonita Capital serving as its trade finance division [2]. - Both Jefferies and Point Bonita were closely associated with First Brands Group, an auto parts supplier that declared bankruptcy with $12 billion in debt [2][4]. Group 2: Financial Exposure - On October 8, 2025, Jefferies disclosed that it and Point Bonita had approximately $715 million in exposure to First Brands' receivables, which constitutes about 25% of Point Bonita's trade finance portfolio [3]. - Following this announcement, Jefferies' stock price dropped by $4.66 per share, or approximately 8%, from $59.10 on October 7, 2025, to $54.44 on October 8, 2025 [3]. Group 3: SEC Investigation Details - The SEC is investigating whether Jefferies provided sufficient information to investors regarding their exposure to the auto business, particularly in light of First Brands' bankruptcy [4]. - The investigation also includes scrutiny of internal controls and potential conflicts of interest within Jefferies and Point Bonita [4]. Group 4: Legal Implications - Bleichmar Fonti & Auld LLP is investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors concerning their significant exposure to First Brands and the ongoing SEC investigation [5].

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 FY 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year, attributed to a "pull forward" in demand due to U.S. tariffs [5]. - Following the financial report, CarMax's stock dropped $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected departure of CEO Bill Nash on November 6, 2025, and a weak preliminary Q3 2025 outlook led to an additional stock drop of over 24% [6]. Group 3: Company Background - CarMax is a leading retailer of used cars, emphasizing a strong customer experience and sustainable demand [3]. - The firm Bleichmar Fonti & Auld LLP, known for representing plaintiffs in securities class actions, is handling the lawsuit against CarMax [10].

Core Viewpoint - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, with concerns regarding the sustainability of its sales growth driven by temporary trade inventory loading rather than genuine consumer demand [1][2]. Group 1: Company Overview - BellRing Brands operates in the convenient nutrition category, primarily known for its brands Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2]. - The company reported that Premier Protein achieved an all-time high in household penetration, indicating strong demand and growth across all channels due to distribution expansion and promotional activities [2]. Group 2: Sales and Stock Performance - On May 5, 2025, BellRing disclosed that several key retailers reduced their weeks of supply, which would negatively impact growth in Q3 2025. Following this announcement, the stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3]. - On August 4, 2025, the company announced disappointing quarterly consumption figures for Premier Protein RTD Shakes, leading to a stock price decline of $17.46, nearly 33%, from $53.64 to $36.18 per share [4].